NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

British Journal of Cancer

Volumn 92, Issue 7, 2005, Pages 1240-1246

  Hamaguchi, T ^a   Matsumura, Y ^a,b   Suzuki, M ^c   Shimizu, K ^c   Goda, R ^c   Nakamura, I ^c   Nakatomi, I ^d   Yokoyama, M ^e   Kataoka, K ^f   Kakizoe, T ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NIPPON KAYAKU CO LTD   (Japan)

^d NanoCarrier Co Ltd   (Japan)

^e KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

DDS; EPR effect; NK105; Paclitaxel; Polymer micelles

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; COPOLYMER; CREMOPHOR; DOXORUBICIN; DRUG CARRIER; GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL; NANOPARTICLE; NK 105; PACLITAXEL; POLYASPARTIC ACID; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CELL STRAIN HT29; CHEMICAL INTERACTION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MICELLE; MOUSE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SENSORY NEUROPATHY; SUSTAINED RELEASE PREPARATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; HUMANS; MICE; NANOSTRUCTURES; NERVOUS SYSTEM; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS;

EID: 20944450473     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602479     Document Type: Article

References (22)

1. Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 23: 71-75
2. Hamaguchi T, Matsumura Y, Shirao Y, Shimada Y, Yamada Y, Muro Y, Okusaka T, Ueno H, Ikeda M, Watanabe N (2003) Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxorubicin. Proc Am Soc Clin Oncol 22: 571
3. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8: 1038-1044
4. Jain RK (1994) Barriers to drug delivery in solid tumours. Sci Am 271: 58-65
5. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y (1993) Block copolymer micelles as vehicles for drug delivery. J Control Rel 24: 119-132
6. Khayat D, Antoine EC, Coeffic D (2000) Taxol in the management of cancers of the breast and the ovary. Cancer Invest 18: 242-260
7. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716
8. Kwon GS, Suwa S, Yokoyama M, Okano T, Sakurai Y (1994) Enhanced tumour accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartic) block copolymer-adriamycin conjugate. J Control Rel 29: 17-23
9. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 65: 271-284
10. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent smancs. Cancer Res 46: 6387-6392
11. Muggia FM (2001) Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 3: 156-162
12. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K (2001) Development of the polymer micelle carrier system for doxorubicin. J Control Rel 74: 295-302
13. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020
14. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014
15. Savic R, Luo L, Eisenberg A, Maysinger D (2003) Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300: 615-618
16. Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P (2003) Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYO-TAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 519: 81-99
17. Unezaki S, Maruyama K, Hosoda J, Nagai I, Koyanagi Y, Nakata M, Ishida O, Iwatsuru M, Tsuchiya S (1996) Direct measurement of the extravasation of polyethylene glycol-coated liposomes into solid tumour tissue by in vivo fluorescence microscopy. Int J Pharmacol 144: 11-17
18. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J (1996) Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14: 1993-1999
19. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268
20. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S (1990) Polymer micelles as novel drug carrie:adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J Control Rel 11: 269-278
21. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K (1991) Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51: 3229-3236
22. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kataoka K (1999) Selective delivery of adriamycin to a solid tumour using a polymeric micelle carrier system. J Drug Target 7: 171-186